USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
THERMALIN DIABETES, INC.
Address:
10000 Cedar Avenue
CLEVELAND, OH
Phone:
N/A
URL:
N/A
EIN:
126053422
DUNS:
802601570
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $2,039,539.00 4
SBIR Phase II $4,469,515.00 1
STTR Phase I $254,997.00 1

Award List:

Clinical Testing of an Insulin Analog

Award Year / Program / Phase:
2009 / STTR / Phase I
Award Amount:
$254,997.00
Agency:
HHS
Principal Investigator:
Research Institution:
CASE WESTERN RESERVE UNIVERSITY
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): The central goal of insulin replacement therapy in the treatment of Type 1 diabetes mellitus (T1DM) is tight control of blood glucose concentration. This Phase I STTR application, submitted by Thermalin Diabetes, Inc., in conjunction with Case Western Reserve… More

Halogenated Insulin: a fast-acting, ultra stable analog.

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$392,091.00
Agency:
HHS
Principal Investigator:
Bruce H. Frank
Abstract:
DESCRIPTION (provided by applicant): A Phase 1 SBIR program of pre-clinical development is proposed focusing on a novel rapid-acting insulin analog for the treatment of diabetes mellitus. Designated Insulin-Cl, our product is a derivative of insulin lispro (the active component of HumalogTM)… More

A Novel 'Zinc-Stapled' Long-Acting Insulin Analog

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$423,635.00
Agency:
HHS
Principal Investigator:
Bruce H. Frank
Abstract:
DESCRIPTION (provided by applicant): A Phase 1 SBIR program of pre-clinical development is proposed focusing on a novel long-acting insulin analog for the basal treatment of diabetes mellitus. Designated Insulin-ZN, our product is a derivative of human ins ulin containing novel zinc-binding sites at… More

Optimized Receptor Binding Profile in an Ultra-Stable, Ultra-Rapid-Acting Insulin

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$622,539.00
Agency:
HHS
Principal Investigator:
Bruce H. Frank – 617-695-0523
Abstract:
DESCRIPTION (provided by applicant): We seek to develop an ultra-fast, zinc-free insulin analog formulation for the treatment of diabetes mellitus. An ultra-fast pharmacokinetic-dynamic (PK/PD) profile promises to enable superior performance of pump therapy (continuous subcutaneous insulin infusion)… More

Chlorolog: Production Scaling and Testing of a Fast-Acting, Ultra-stable Insulin

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$4,469,515.00
Agency:
HHS
Principal Investigator:
Bruce H. Frank – 317-846-4233
Abstract:
DESCRIPTION (provided by applicant): We seek to develop a novel insulin analog to enhance the safety and efficacy of insulin pump therapy with broad application to the Artificial Pancreas Project ( smart pumps ). A proprietary approach is proposed basedon the favorable physico-chemical properties… More

Manipulating Aromaticity: characterization of an ultra-rapid insulin analog

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$601,274.00
Agency:
HHS
Principal Investigator:
Bruce H. Frank – 317-846-4233
Abstract:
DESCRIPTION (provided by applicant): We seek to develop an ultra-fast insulin analog formulation for the treatment of diabetes mellitus. Ultra-fast pharmacokinetic/dynamic (PK/PD) promises to enable superior performance of pump therapy (continuous subcutaneous insulin infusion; CSII) with enhanced… More